Literature DB >> 2004030

Management of myelofibrosis with intermittent hydroxyurea.

A Manoharan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2004030     DOI： 10.1111/j.1365-2141.1991.tb07989.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

1.  Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis.

Authors:  Koji Sasaki; Jason R Gotlib; Ruben A Mesa; Kate J Newberry; Farhad Ravandi; Jorge E Cortes; Patrick Kelly; Jeffery L Kutok; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2015-02-17

2.  Emerging therapeutic options for myelofibrosis: a Canadian perspective.

Authors:  Vikas Gupta; Lynda Foltz; Shireen Sirhan; Lambert Busque; A Robert Turner
Journal:  Am J Blood Res       Date:  2012-09-23

3.  How I treat splenomegaly in myelofibrosis.

Authors:  F Cervantes
Journal:  Blood Cancer J       Date:  2011-10-07       Impact factor: 11.037

4.  Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

Authors:  M B Agarwal; Hemant Malhotra; Prantar Chakrabarti; Neelam Varma; Vikram Mathews; Jina Bhattacharyya; Tulika Seth; K Gayathri; Hari Menon; P G Subramanian; Ajay Sharma; Maitreyee Bhattacharyya; Jay Mehta; A K Vaid; Sandeep Shah; Shyam Aggarwal; P K Gogoi; Reena Nair; Usha Agarwal; Subhash Varma; S V S S Prasad; Marie Therese Manipadam
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Jan-Mar

5.  A systematic review of non-standard dosing of oral anticancer therapies.

Authors:  Faouzi Djebbari; Nicola Stoner; Verna Teresa Lavender
Journal:  BMC Cancer       Date:  2018-11-22       Impact factor: 4.430

6.  Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.

Authors:  Novella Pugliese; Claudia Giordano; Davide Nappi; Luigiana Luciano; Claudio Cerchione; Mario Annunziata; Beniamino Casale; Elena Crisà; Maria Rosaria Villa; Luca Pezzullo; Maria Iovine; Marco Picardi; Francesco Grimaldi; Fabrizio Pane; Vincenzo Martinelli
Journal:  Cancer Med       Date:  2019-04-17       Impact factor: 4.452

7.  Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis.

Authors:  Arumugam Manoharan; Rosalie Gemmell; Lauren Cavanaugh; Noor Shadood
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.